Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
May 21 2024 - 6:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today the appointment of Naseem Amin, M.D. to its board
of directors, effective May 17, 2024. Dr. Amin, a highly successful
executive who brings global industry and leadership experience to
Avadel, currently serves as Chief Executive Officer of Orphalan SA.
“On behalf of the entire Avadel team, we are
excited to welcome Dr. Amin to our board of directors,” said
Geoffrey M. Glass, Avadel Chairman of the Board. “Dr. Amin’s
extensive experience in identifying, developing, and
commercializing new medicines for dynamic growth-oriented companies
will be a great addition to the Avadel board as we continue to
execute on the commercial launch of LUMRYZ and potentially expand
its use into pediatrics and idiopathic hypersomnia.”
Dr. Amin brings to Avadel thirty years of
international industry executive leadership and expertise in
business development, venture capital, and research and
development. He is currently Chief Executive Officer of Orphalan
SA, a role he has held since June 2017. Dr. Amin previously served
as Executive Chairman at Arix Bioscience plc, a global venture
capital company focused on investing in life sciences, until April
2021, and was Venture Partner at Advent Life Sciences until 2020.
Earlier, he was the Chief Scientific Officer at Smith and Nephew
until 2014, overseeing corporate R&D, divisional manufacturing,
and product development functions. Previous to that, Dr. Amin was
Senior Vice President, Business Development, at Biogen Idec from
2005 to 2009, was with Genzyme Corporation from 1999 to 2005, and
began his career at Baxter Healthcare Corporation. Dr. Amin
received his medical degree from the Royal Free School of Medicine,
London, and his MBA from the Kellogg Graduate School of Management,
Northwestern University.
“I am thrilled to join the Avadel board at this
exciting time in the company’s history, as they continue to execute
on the commercial launch of LUMRYZ for the treatment of narcolepsy,
as well as potentially expand LUMRYZ’s use into pediatrics and
idiopathic hypersomnia. LUMRYZ represents an extraordinary
breakthrough for patients, and I am eager to leverage my 30 years
of experience in growing and developing companies to support
Avadel’s continued success and its impact on people with sleep
disorders,” said Dr. Naseem Amin.
About Avadel Pharmaceuticals
plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to
transform lives. Our approach includes applying innovative
solutions to the development of medications that address the
challenges patients face with current treatment options. Avadel’s
commercial product, LUMRYZ™, was approved by the U.S. Food
& Drug Administration (FDA) as the first and only
once-at-bedtime oxybate for the treatment of cataplexy or excessive
daytime sleepiness (EDS) in adults with narcolepsy. For more
information, please visit www.avadel.com.
Cautionary Disclosure Regarding
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements relate to our future expectations,
beliefs, plans, strategies, objectives, results, conditions,
financial performance, prospects or other events. Such
forward-looking statements include, but are not limited to,
expectations regarding the anticipated contribution of the members
of our board of directors to our operations and progress. In some
cases, forward-looking statements can be identified by the use of
words such as “will,” “may,” “could,” “believe,” “expect,” “look
forward,” “on track,” “guidance,” “anticipate,” “estimate,”
“project,” “next steps” and similar expressions and the negatives
thereof (if applicable).
The Company’s forward-looking statements are based
on estimates and assumptions that are made within the bounds of our
knowledge of our business and operations and that we consider
reasonable. However, the Company’s business and operations are
subject to significant risks, and, as a result, there can be no
assurance that actual results and the results of the company’s
business and operations will not differ materially from the results
contemplated in such forward-looking statements. Factors that could
cause actual results to differ from expectations in the Company’s
forward-looking statements include the risks and uncertainties
described in the “Risk Factors” section of Part I, Item 1A of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, which was filed with the Securities and Exchange
Commission (SEC) on February 29, 2024, and subsequent SEC
filings.
Forward-looking statements speak only as of the
date they are made and are not guarantees of future performance.
Accordingly, you should not place undue reliance on forward-looking
statements. The Company does not undertake any obligation to
publicly update or revise our forward-looking statements, except as
required by law.
Investor Contact:Courtney
MogerleyStern Investor Relations, Inc.Courtney.Mogerley@sternir.com
(212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com(609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2024 to Jun 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Jun 2023 to Jun 2024